JUN 06, 2017 1:24 PM PDT

Protecting Beta Cells to Treat Type 1 Diabetes

WRITTEN BY: Kara Marker

A new way to treat - and maybe prevent - type 1 diabetes revolves around protecting beta cells, the cells produced by the pancreas to make insulin. Jackson Laboratory researchers conducted a new study published in the Journal of Immunology focused on finding the best way to provide this protection.

Human-stem-cell-derived beta cells that have formed islet-like clusters in a mouse. Credit: Harvard Magazine

The pancreas produces beta cells to make insulin, which in turn transports glucose to bring energy to cells all over the body. Beta cells are the primary target of autoreactive T cells activated by B cells during the development of type 1 diabetes (T1D), which is why people with this condition have to receive insulin injections.

When beta cells damaged by autoreactive T cells can’t produce insulin to carry glucose like normal, glucose builds up in the blood, nerves, and blood vessels, and organs damage characteristic of T1D results. For their anti-T1D approach, Jackson Laboratory researchers are going straight to the source: B cells.

“If you can target those antigen-presenting B-cells, that could be potentially a very effective disease intervention," said lead author David Serreze, PhD. "Our approach targets an appropriate population of the B cells among the white blood cells, resulting in inactivation of the cascade of autoimmunity against the insulin-producing pancreatic beta cells, and hence subsequently blocking diabetes development."

While targeting the B cells that ultimately activate autoreactive T cells would protect insulin-producing beta cells, there are other B cells that provide healthy actions that scientists wouldn’t want squandered. An ideal approach would be to block the B cells that activate autoreactive T cells without destroying the healthy B cells that activate healthy T cell responses to invading pathogens.

Serreze’s study applied a gene manipulation approach to find the right target for the right B cells. They used non-obese diabetic mice treated with a B cell pathway inhibitor called AID/RAD51. The mice treated with this inhibitor had larger populations of B cells that suppressed autoreactive T cell responses instead of activating them, a result that also greatly reduced T1D development compared to mice who only received a placebo.

"To combat T1D, we're taking out this whole pathway to block autoreactive cells. But on the flip side, you may want to keep this pathway active if you want to keep antitumor immune responses in place,” Serreze explained. “Ultimately, this approach could potentially be applicable to any autoimmune disease that has a B-cell component."

Source: Jackson Laboratory

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
FEB 17, 2020
Immunology
FEB 17, 2020
Another HIV vaccine attempt fizzles out
Years of work and over $100 million in study costs have been abandoned after an HIV-vaccine tested in South Africa faile ...
APR 02, 2020
Immunology
APR 02, 2020
Transforming T Cells into Powerful Memory Cells That Target Cancer
New cancer treatments are now based on harnessing the power of the human body’s own immune cells to get the job do ...
APR 07, 2020
Microbiology
APR 07, 2020
Second COVID-19 Vaccine Enters Human Trials
Yesterday, Inovio Pharmaceuticals, Inc. announced that it will begin human trials on a potential vaccine for COVID-19.
APR 09, 2020
Drug Discovery & Development
APR 09, 2020
Does Hydroxychloroquine Really Work Against COVID-19?
Although US President Donald Trump is a strong supporter of antimalarial drug Hydroxychloroquine as a treatment for COVI ...
APR 13, 2020
Drug Discovery & Development
APR 13, 2020
Are COVID-19 Antibody Tests a Back-to-Work Pass?
Although treatments and vaccines against COVID-19 may still be months away, antibody tests are becoming more widespread. ...
APR 26, 2020
Microbiology
APR 26, 2020
Researchers Design A Polio Vaccine That Won't Cause Polio
Sustained, intense efforts to vaccinate were getting the world very close to eradicating polio, but the vaccine itself o ...
Loading Comments...